This run could be short-lived.

Intellia Therapeutics Inc. NTLA shares are up on Monday following the FDA’s decision to lift the clinical hold on its ...

Is On Investors’ Radar Intellia Therapeutics (NTLA) has drawn attention after a recent stretch of positive returns, with the stock up over the month, the past 3 months, and over the past year. For ...

Intellia said the FDA removed the clinical hold on application for the Phase 3 clinical trial of nexiguran ziclumeran. The study is a randomized, double-blind, placebo-controlled trial evaluating the ...

Intellia TherapeuticsNTLA stock shot higher Tuesday after the Food and Drug Administration said it would allow the company to restart a study of its gene-editing drug in patients with polyneuropathy.

The biotech published a readout of a phase 2 trial of its hereditary angioedema treatment. The results were generally positive, but for one analyst they weren't positive enough. Intellia, which is a ...

Sometimes with biotech stocks, what a company considered to be good news clashes with what the market is expecting. That was true on Oct. 24 when Intellia Therapeutics (NASDAQ: NTLA) announced some ...

Intellia is now able to continue both Phase III trials of nex-z. Credit: Piotr Swat / Shutterstock.com (Piotr Swat / Shutterstock.com) The US Food and Drug Administration (FDA) has released the ...

Thursday was hardly a good day to be a shareholder of Intellia Therapeutics (NASDAQ: NTLA). After the biotech delivered some news from the lab and witnessed one analyst's negative reaction to it, the ...